The GLP-1 panic is alive and well
The need-to-know in biotech this morning: —The arrival of Scion Life Sciences —GLP-1 drug panic —The weight of expectations on Eli Lilly
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.
What's Your Reaction?
